Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of “Moderate Buy” from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $21.75.

VTYX has been the subject of several research analyst reports. Lifesci Capital raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Canaccord Genuity Group lowered their price objective on shares of Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Oppenheimer raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Tuesday, March 12th. Finally, Wells Fargo & Company raised shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th.

Ventyx Biosciences Stock Down 1.2 %

Shares of NASDAQ VTYX opened at $4.85 on Monday. The firm has a 50-day simple moving average of $6.08 and a 200-day simple moving average of $4.90. The stock has a market capitalization of $341.93 million, a price-to-earnings ratio of -1.47 and a beta of 0.48. Ventyx Biosciences has a 52 week low of $1.87 and a 52 week high of $40.58.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.08. During the same quarter last year, the firm earned ($0.62) EPS. As a group, equities research analysts expect that Ventyx Biosciences will post -2.55 EPS for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in Ventyx Biosciences by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,506 shares of the company’s stock worth $52,000 after buying an additional 739 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Ventyx Biosciences by 9.8% during the third quarter. Arizona State Retirement System now owns 11,671 shares of the company’s stock valued at $405,000 after buying an additional 1,043 shares during the period. Teacher Retirement System of Texas grew its stake in Ventyx Biosciences by 13.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 11,642 shares of the company’s stock worth $404,000 after acquiring an additional 1,376 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ventyx Biosciences by 36.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,855 shares of the company’s stock valued at $273,000 after acquiring an additional 2,078 shares during the last quarter. Finally, JSF Financial LLC purchased a new position in shares of Ventyx Biosciences during the 3rd quarter worth $208,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.